BioCryst Pharmaceuticals, Inc. (BCRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 6.57 |
| Open | 6.63 |
| Bid | 5.60 x 100 |
| Ask | 6.48 x 1600 |
| Day's Range | 6.43 - 6.82 |
| 52 Week Range | 4.03 - 8.96 |
| Volume | |
| Avg. Volume | 3,631,785 |
| Market Cap | 1.333B |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) is possibly approaching a major achievement in its business, so we would...
- GuruFocus.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ...
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
- GuruFocus.com
Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
© 2024 Yahoo. All rights reserved.